Latest:
Treatment Considerations for Consolidation Durvalumab in Unresectable ES NSCLC
The panel discusses treatment considerations for consolidation durvalumab.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Adria Suarez Mora, MD
Latest:
Dr. Suarez Mora On Sequential Sampling of IP Fluid During Chemotherapy
Adria Suarez Mora, MD, second-year fellow at UPMC Magee-Womens Hospital, discusses how sequential sampling of intraperitoneal fluid during chemotherapy help better define the immunogenic effects of the treatment.
Adriana Rossi, MD, Weill Cornell Medical College
Latest:
Insights from IMS 2024 on Counseling Patients with Multiple Myeloma about CAR T-cell Therapy and Connecting to Referral Centers
Panelists discuss how community providers can implement strategies and utilize resources to effectively connect patients to referral centers for chimeric antigen receptor T-cell therapy, while addressing how to initiate conversations about the therapy and counsel patients regarding potential adverse events.
Adrienne Phillips, MD, MPH
Latest:
Dr Phillips on the Shifting Treatment Paradigm For CAR T-Cell Therapy in LBCL
Adrienne Phillips, MD, MPH, discusses the impact of CAR T-cell therapy on the treatment paradigm for patients with large B-cell lymphoma, highlighting key advancements in the decision-making process for CAR T-cell therapy selection.
Agnieszka Janus, MD, PhD
Latest:
Dr. Janus on the Role of Moxetumomab Pasudotox in Hairy Cell Leukemia
Agnieszka Janus, MD, PhD, discusses the efficacy and safety of moxetumomab pasudotox as a treatment option for patients with hairy cell leukemia. This agent was approved by the FDA in September 2018 for the treatment of adult patients with hairy cell leukemia who have received at least 2 prior lines of therapy, including a purine nucleoside analog.
Agustin A. Garcia, MD
Latest:
Novel Agents Signal Progress in the Management of Platinum-Resistant Ovarian Cancer
The evaluation of noncytotoxic agents for
the treatment of epithelial ovarian cancer
has produced encouraging findings in
recent months, which has led to the approval of
new agents with novel mechanisms of action
and continuing studies into many more potential
therapies.
Ahmed A. Hussein Aly, MD, PhD
Latest:
TRT in Patients With Prostate Cancer on Active Surveillance: Are We Really Putting Gas on Fire?
Investigators hypothesized that testosterone replacement does not have a negative impact on the oncologic outcomes of treatment-naive patients with prostate cancer on surveillance and they performed a retrospective review of an institutional active surveillance prostate cancer database.